(Q40581680)

21 September 2017

1 reference

title

Is there a role for epoprostenol in the management of heart failure? (English)

1 reference

21 September 2017

G A Haywood

1

1 reference

21 September 2017

K F Adams

series ordinal

2

1 reference

21 September 2017

M Gheorghiade

series ordinal

3

1 reference

21 September 2017

W J McKenna

series ordinal

4

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 January 1995

1 reference

American Journal of Cardiology

21 September 2017

published in

1 reference

21 September 2017

volume

75

1 reference

21 September 2017

issue

3

1 reference

21 September 2017

page(s)

44A-50A

1 reference

Prostaglandin I2 (PGI2) enhances calcium current in guinea-pig ventricular heart cells

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Drug-induced conditioning in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Intermittent, continuous outpatient dobutamine infusion in the management of congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Cloning and expression of a cDNA for the human prostacyclin receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Augmentation of cardiac function in end-stage heart failure by combined use of dobutamine and amrinone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Thromboxane, prostaglandin and leukotriene receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

The development of positive inotropic agents for chronic heart failure: how have we gone astray?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Prostacyclin therapy in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Prostacyclin I2 (PGI2) increases left ventricular ejection fraction (LVEF).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

The effects of vasodilation with prostacyclin on oxygen delivery and uptake in critically ill patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Relationship between oxygen uptake and oxygen delivery in septic patients: effects of prostacyclin versus dobutamine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Prostacyclin and right ventricular function in patients with pulmonary hypertension associated with ARDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Different effects of prostacyclin and phentolamine on delivery-dependent O2 consumption and skin microcirculation after cardiac surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Central hemodynamics and right ventricular function after coronary artery bypass surgery. A comparison of prostacyclin, sodium nitroprusside, and nitroglycerin for treatment of postcardiac surgical hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Comparison between prostaglandin E1 and epoprostenol (prostacyclin) in infants after heart surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Nitric oxide and prostacyclin lower suprasystemic pulmonary hypertension after cardiopulmonary bypass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Acute pulmonary hypertensive crisis in a patient with primary pulmonary hypertension treated by both epoprostenol (prostacyclin) and nitroprusside

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Contractile responses to prostacyclin (PGI2) of isolated human saphenous and rat venous tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Physiologic role of coronary PGI2 and PGE2 in modulating coronary vascular response to sympathetic stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Myocardial ischemia during intravenous prostacyclin administration: hemodynamic findings and precautionary measures

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Prostaglandin I2 versus prostaglandin E2 in dogs with and without low cardiac output. Differential effects on renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Effects of dobutamine and prostacyclin on cerebral blood flow velocity in septic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Inhaled nitric oxide for the adult respiratory distress syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Adenosine infusion for the reversal of pulmonary vasoconstriction in biventricular failure. A good test but a poor therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Inhaled nitric oxide leading to pulmonary edema in stable severe heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Right ventricular ejection fraction: An indicator of increased mortality in patients with congestive heart failure associated with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Factors influencing the one-year mortality of dilated cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Usefulness of OPC-8212, a quinolinone derivative, for chronic congestive heart failure in patients with ischemic heart disease or idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Effect of prostacyclin PGI2 on cardiopulmonary bypass-induced lung injury.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Prostaglandin modulation of early afterdepolarizations and ventricular tachyarrhythmias induced by cesium chloride combined with efferent cardiac sympathetic stimulation in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Side effects of amrinone therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Advanced congestive heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980382-8

10.1016/S0002-9149(99)80382-8

7 January 2021

Identifiers

DOI

1 reference

21 September 2017

1 reference